Clinical Trial Update: A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tocilizumab (RoActemra/Actemra) versus placebo in systemic sclerosis has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis

Drugs mentioned

• RoActemra/Actemra (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Sclerosis, Systemic | Phase 3 | Status: COMPLETED | Results posted: 2015-11-05